Skip to main content

Advertisement

Table 2 Results from the multivariate generalized linear mixed modeling under the Bayesian framework. The data represent the median and 95% credible intervals for the outcome measures MDS-UPDRS-II, MDS-UPDRS-I, and Imbalance

From: Predicting the multi-domain progression of Parkinson’s disease: a Bayesian multivariate generalized linear mixed-effect model

  Median 2.50% 97.50%
MDS-UPDRS-II (motor)
 Intercept 13.522 0.076 25.197
 Time −0.042 −0.095 0.011
 Age at Baseline 0.035 −0.147 0.211
 Education −0.108 −0.604 0.419
 Gender (=Male) 0.805 −2.381 3.904
 DOI* 0.549 0.169 0.919
 HAMD* 0.283 0.087 0.492
 MoCA* −0.320 −0.584 −0.052
 LEDD 1.066 −0.570 2.612
MDS-UPDRS-I (non-motor)
 Intercept 26.351 10.126 38.947
 Time −0.016 −0.075 0.046
 Age at Baseline 0.075 −0.098 0.250
 Education* −0.575 −1.075 −0.107
 Gender (=Male) −1.925 −5.203 1.036
 DOI 0.037 −0.306 0.397
 HAMD* 0.439 0.217 0.693
 MoCA −0.311 −0.609 0.008
 LEDD 0.360 −1.250 1.993
Imbalance
 Intercept 6.096 −6.903 23.289
 Time* −0.109 −0.579 −0.001
 Age at Baseline 0.181 −0.021 0.853
 Education −0.148 −1.184 0.823
 Gender (=Male)* −4.657 −21.182 −0.790
 DOI 0.312 −0.027 2.233
 HAMD 0.023 −0.302 0.541
 MoCA* −0.589 −2.336 −0.164
 LEDD* 2.827 0.675 11.893
  1. Abbreviations: MDS-UPDRS the Movement Disorder Society-sponsored Unified Parkinson’s Disease Rating Scale, DOI duration of illness, HAMD Hamilton Depression Rating Scale, MoCA the Montreal Cognitive Assessment, LEDD Levodopa equivalent daily dose
  2. *95% credible interval does not include 0, indicating the signifiance